Amélie Cattin1,2, Tomas Raul Wiche Salinas1,2, Annie Gosselin1, Delphine Planas1,2, Barbara Shacklett3, Eric A Cohen2,4, Maged P Ghali5, Jean-Pierre Routy6,7, Petronela Ancuta1,2. 1. CHUM-Research Centre. 2. Département de microbiologie, infectiologie et immunologie, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada. 3. University of California Davis, Davis, California, USA. 4. Institut de Recherche Clinique de Montréal. 5. Division of Gastroenterology and Hepatology. 6. Division of Hematology. 7. Chronic Viral Illness Service and Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.
Abstract
OBJECTIVE: The aim of this study was to explore the contribution of blood and colon myeloid cells to HIV persistence during antiretroviral therapy (ART). DESIGN: Leukapheresis was collected from HIV-infected individuals with undetectable plasma viral load during ART (HIV + ART; n = 15) and viremics untreated (HIV+; n = 6). Rectal sigmoid biopsies were collected from n = 8 HIV+ART. METHODS: Myeloid cells (total monocytes (Mo), CD16/CD16 Mo, CD1c dendritic cells) and CD4 T cells were isolated by magnetic-activated cell sorting (MACS) and/or fluorescence-activated cell sorting (FACS) from peripheral blood. Matched myeloid and CCR6CD4 T cells were isolated from blood and rectal biopsies by FACS. Levels of early (RU5 primers), late (Gag primers) and/or integrated HIV-DNA (Alu/HIV primers) were quantified by nested real-time PCR. Replication-competent HIV was amplified by co-culturing cells from HIV-positive individuals with CD3/CD28-activated CD4 T cells from uninfected donors. RESULTS: Early/late but not integrated HIV reverse transcripts were detected in blood myeloid subsets of four out of 10 HIV+ART; in contrast, integrated HIV-DNA was exclusively detected in CD4 T cells. In rectal biopsies, late HIV reverse transcripts were detected in myeloid cells and CCR6CD4 T cells from one out of eight and seven out of eight HIV+ART individuals, respectively. Replication-competent HIV was outgrown from CD4 T cells but not from myeloid of untreated/ART-treated HIV-positive individuals. CONCLUSION: In contrast to CD4 T cells, blood and colon myeloid cells carry detectable HIV only in a small fraction of HIV+ART individuals. This is consistent with the documented resistance of Mo to HIV infection and the rapid turnover of Mo-derived macrophages in the colon. Future assessment of multiple lymphoid and nonlymphoid tissues is required to include/exclude myeloid cells as relevant HIV reservoirs during ART.
OBJECTIVE: The aim of this study was to explore the contribution of blood and colon myeloid cells to HIV persistence during antiretroviral therapy (ART). DESIGN: Leukapheresis was collected from HIV-infected individuals with undetectable plasma viral load during ART (HIV + ART; n = 15) and viremics untreated (HIV+; n = 6). Rectal sigmoid biopsies were collected from n = 8 HIV+ART. METHODS: Myeloid cells (total monocytes (Mo), CD16/CD16 Mo, CD1c dendritic cells) and CD4 T cells were isolated by magnetic-activated cell sorting (MACS) and/or fluorescence-activated cell sorting (FACS) from peripheral blood. Matched myeloid and CCR6CD4 T cells were isolated from blood and rectal biopsies by FACS. Levels of early (RU5 primers), late (Gag primers) and/or integrated HIV-DNA (Alu/HIV primers) were quantified by nested real-time PCR. Replication-competent HIV was amplified by co-culturing cells from HIV-positive individuals with CD3/CD28-activated CD4 T cells from uninfected donors. RESULTS: Early/late but not integrated HIV reverse transcripts were detected in blood myeloid subsets of four out of 10 HIV+ART; in contrast, integrated HIV-DNA was exclusively detected in CD4 T cells. In rectal biopsies, late HIV reverse transcripts were detected in myeloid cells and CCR6CD4 T cells from one out of eight and seven out of eight HIV+ART individuals, respectively. Replication-competent HIV was outgrown from CD4 T cells but not from myeloid of untreated/ART-treated HIV-positive individuals. CONCLUSION: In contrast to CD4 T cells, blood and colon myeloid cells carry detectable HIV only in a small fraction of HIV+ART individuals. This is consistent with the documented resistance of Mo to HIV infection and the rapid turnover of Mo-derived macrophages in the colon. Future assessment of multiple lymphoid and nonlymphoid tissues is required to include/exclude myeloid cells as relevant HIV reservoirs during ART.
Authors: Frederic Geissmann; Markus G Manz; Steffen Jung; Michael H Sieweke; Miriam Merad; Klaus Ley Journal: Science Date: 2010-02-05 Impact factor: 47.728
Authors: Amy E Baxter; Rebecca A Russell; Christopher J A Duncan; Michael D Moore; Christian B Willberg; Jose L Pablos; Andrés Finzi; Daniel E Kaufmann; Christina Ochsenbauer; John C Kappes; Fedde Groot; Quentin J Sattentau Journal: Cell Host Microbe Date: 2014-11-20 Impact factor: 21.023
Authors: Jenna B Honeycutt; William O Thayer; Caroline E Baker; Ruy M Ribeiro; Steven M Lada; Youfang Cao; Rachel A Cleary; Michael G Hudgens; Douglas D Richman; J Victor Garcia Journal: Nat Med Date: 2017-04-17 Impact factor: 53.440
Authors: Marta Massanella; Wendy Bakeman; Pasiri Sithinamsuwan; James L K Fletcher; Nitiya Chomchey; Somporn Tipsuk; Thep Chalermchai; Jean-Pierre Routy; Jintanat Ananworanich; Victor G Valcour; Nicolas Chomont Journal: J Virol Date: 2019-12-12 Impact factor: 5.103